Difficulty: Medium
Average Score: 73%
Practice
Which of the following chromosomal abnormalities of childhood ALL carries the highest risk of relapse despite intensive chemotherapy?
Correct answer
A
Rationale
In pediatric acute lymphoblastic leukemia (ALL), the chromosomal abnormality t(9;22), also known as the Philadelphia chromosome, carries the highest risk of relapse despite intensive chemotherapy. This is because it is associated with the BCR-ABL fusion gene, which confers a poorer prognosis and resistance to treatment compared to other chromosomal abnormalities.
Option B, t(4;11), is associated with MLL rearrangements and has a generally poor prognosis, but it does not carry as high a risk of relapse as t(9;22) in childhood ALL.
Option C, hypodiploidy, is also a high-risk feature in childhood ALL, but it does not have as consistently poor outcomes in terms of relapse risk as t(9;22).
Option D, t(1;19), is associated with the E2A-PBX1 fusion gene and is considered an intermediate risk factor in childhood ALL. While it may have a higher risk of relapse compared to standard-risk ALL, it is not as high as the risk associated with t(9;22).
In an educational context, understanding the impact of specific chromosomal abnormalities on the prognosis of childhood ALL is crucial for healthcare providers involved in the care of pediatric oncology patients. Knowing which abnormalities carry a higher risk of relapse can help guide treatment decisions and monitoring strategies to improve patient outcomes. It also underscores the importance of tailoring treatment approaches based on the molecular characteristics of the leukemia to optimize therapeutic efficacy and minimize the risk of relapse.
Option B, t(4;11), is associated with MLL rearrangements and has a generally poor prognosis, but it does not carry as high a risk of relapse as t(9;22) in childhood ALL.
Option C, hypodiploidy, is also a high-risk feature in childhood ALL, but it does not have as consistently poor outcomes in terms of relapse risk as t(9;22).
Option D, t(1;19), is associated with the E2A-PBX1 fusion gene and is considered an intermediate risk factor in childhood ALL. While it may have a higher risk of relapse compared to standard-risk ALL, it is not as high as the risk associated with t(9;22).
In an educational context, understanding the impact of specific chromosomal abnormalities on the prognosis of childhood ALL is crucial for healthcare providers involved in the care of pediatric oncology patients. Knowing which abnormalities carry a higher risk of relapse can help guide treatment decisions and monitoring strategies to improve patient outcomes. It also underscores the importance of tailoring treatment approaches based on the molecular characteristics of the leukemia to optimize therapeutic efficacy and minimize the risk of relapse.